Xifia

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xifia

Quick Facts Description
Active ingredient Cefixime
Form Oral tablets, capsules, suspension
Pharmacological class Third-Generation Cephalosporin Antibiotic
General purpose Elimination of susceptible bacterial infection
Origin Synthetic

Identity and Classification of Xifia

Xifia is the trade name for a highly effective, prescription-only synthetic medicine whose sole active ingredient is Cefixime, which is recognized as an essential medicine. It is primarily defined as an antibiotic, specifically belonging to the cephalosporin family. This medicine is a single-active-ingredient product intended for oral administration, typically manufactured and positioned as a reliable agent for treating infections in both adults and pediatric patients. The structure and function of Cefixime is distinct from other antimicrobial agents.


Xifia’s Place as a Third-Generation beta-Lactam

The medicine is further classified as a third-generation beta-lactam antibiotic, indicating a highly developed structure that gives it specialized capability. The primary mechanism principle is its bactericidal action, which means the medicine actively kills target bacteria by disrupting the synthesis of their protective cell walls. This sub-classification is characterized by an improved resistance profile against certain common bacterial enzymes (beta-lactamases) that deactivate older antibiotics. This makes Xifia clinically recognized for its reliable efficacy in scenarios where the infecting microbe is known to be susceptible to advanced cephalosporins. The general therapeutic purpose of the drug is to eliminate microbial invaders, supporting the body's processes toward recovery by addressing the underlying bacterial presence.


Available Pharmaceutical Forms of Cefixime

Cefixime is prepared as a pharmaceutical entity intended for oral administration and is available in forms that facilitate use across different patient groups. It is commonly supplied as oral tablets and oral capsules, which contain the Cefixime and essential excipients for stability and absorption. Notably, the drug is formulated as an oral suspension, a liquid form requiring an aqueous vehicle, which provides a crucial alternative for pediatric patients or any individual who may encounter difficulty swallowing solid dosage forms. The suspension form of Cefixime is often flavored, a differentiating factor designed to enhance compliance among younger patients.

Regulatory References

  1. WHO Essential Medicines List
  2. MedlinePlus Cefixime Summary (NIH)
  3. U.S. Food and Drug Administration (FDA)
  4. Third-Generation Cephalosporins (NIH StatPearls)

What side effects are possible with Xifia?

Possible side effects and safety information

The safety profile for Xifia (Cefixime) is documented through regulatory channels, outlining expected adverse reactions and defining constraints for its use. Reactions are grouped by frequency and physiological system, based on official regulatory standards.

Classification Examples of Officially Documented Adverse Reactions
Common (up to 1 in 10) Diarrhoea, which is frequently noted as transient, and loose stools.
Uncommon (up to 1 in 100) Abdominal pain, nausea, vomiting, headache, rash, and transient increases in hepatic enzymes.
Rare to Very Rare Flatulence, vertigo, hypersensitivity reactions, drug fever, and serious blood disorders such as haemolytic anaemia or pancytopenia.

Serious adverse reactions are explicitly detailed in regulatory documents and include Anaphylactic/Anaphylactoid reactions and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The risk of Clostridium difficile-Associated Diarrhea (CDAD) is also a documented safety concern that may manifest during or after the completion of therapy.

Safety notes specify that use is contraindicated in patients with a history of hypersensitivity to any cephalosporin or a severe reaction to any other beta-lactam agent. Caution is also noted in patients with a history of penicillin allergy due to potential cross-allergenicity.

Specific population considerations include patients with Renal Impairment, where caution is required due to an increased risk of encephalopathy if renal function is markedly reduced. Safety has not been established in infants younger than six months. The official documentation confirms that adverse reactions may occur more frequently in older adults due to expected physiological changes.

Overdose and Emergency Response

Xifia Overdose and when to seek help

Official regulatory documentation states that specific clinical experience with acute Cefixime (Xifia) overdose is limited. The manifestations of overdose are generally expected to align with the known severe adverse reaction profile associated with high systemic exposure.


Documented Manifestations and Serious Outcomes

Overdose may affect the Central Nervous System, potentially resulting in encephalopathy or seizures. Serious outcomes documented in regulatory warnings also include severe organ damage, such as acute renal failure, and life-threatening systemic reactions like anaphylactic shock or severe cutaneous events. The risk of CNS toxicity is specifically noted as elevated, particularly in cases of overdose, in patients with pre-existing renal impairment.


Emergency Actions and Management

Immediate medical attention is mandated for severe signs of overdose, including the onset of a seizure, any difficulty with breathing, or the appearance of shock. The medicine should be discontinued immediately if these serious manifestations occur.

Management of Cefixime overdose is symptomatic and supportive because official regulatory information confirms that no specific antidote exists. Procedural steps, such as the administration of anticonvulsant therapy if seizures are clinically indicated, are described. Regulatory constraints also note that dialysis does not remove the medicine from the circulation in significant quantities.

Therapeutic Uses of Xifia

What Xifia Treats: Main Uses and Benefits

Xifia (Cefixime) is commonly used to help with acute bacterial infections across various systems. It is relevant when supportive symptom management is appropriate in situations where symptoms create noticeable interference with daily functioning.

Core Therapeutic Scope

The medication is applied in addressing conditions associated with acute or disruptive episodes like Otitis Media (middle ear infection), Pharyngitis/Tonsillitis (throat and tonsil infections), Acute Exacerbations of Chronic Bronchitis (AECB), and Uncomplicated Urinary Tract Infections (UTIs), as well as specific infections such as Uncomplicated Gonorrhea. It is often used during phases when symptoms become more noticeable in both adult and pediatric patients.

It is used for relief from symptoms that become more disruptive during flare-ups, such as acute pain, fever, and bronchial or urinary discomfort. The therapeutic approach supports the body's natural processes during acute or disruptive episodes, offering symptomatic relief.

“The therapeutic approach supports the body's natural processes during acute or disruptive episodes, offering symptomatic relief.”

This approach contributes to improved comfort by providing assistance in symptom stabilization and helps to ease the symptoms that create noticeable physiological strain.


Quick Facts

Quick Fact Relief Focus
Acute Ear/Throat Discomfort Symptoms related to inflammatory or irritative states
Urinary Symptoms (Dysuria) Symptoms linked to organ-specific functional stress
Bronchial Distress Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Who can and cannot use Xifia?

Xifia (Cefixime) eligibility is formally defined by regulatory documents based on a patient’s history of allergies, age, and organ function. The regulatory profile establishes clear boundaries for who may safely use the medicine.

Absolute Restrictions (Contraindications)

Xifia must not be used by any patient with a known hypersensitivity or allergy to Cefixime or to any medicine belonging to the cephalosporin class of antibiotics.

Conditional and Restricted Use

Population Group Eligibility Status (Regulatory Wording)
Age Eligibility Approved for use in adults and pediatric patients six months of age or older. Use is not recommended for infants under six months, as safety and efficacy have not been established.
Renal Function Requires caution for patients with markedly impaired renal function. Pediatric patients with renal insufficiency are also not recommended for treatment.
Pregnancy/Lactation Use in pregnancy is conditional and should occur only if clearly needed. For nursing mothers, regulatory guidance suggests considering the temporary discontinuation of nursing during the treatment period.
Comorbidities Caution is advised for individuals with a history of penicillin allergy or a history of colitis. Furthermore, the chewable tablet form is not recommended for patients with Phenylketonuria (PKU) due to an excipient restriction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Xifia (Cefixime) outlines specific pharmacokinetic and pharmacodynamic relationships with certain co-administered substances. This profile is defined by official label warnings regarding altered drug exposure, coagulation effects, and interference with laboratory procedures.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Outcome (Regulatory Description)
Carbamazepine Co-administration has been associated with elevated Carbamazepine levels, reported as a pharmacokinetic interaction in postmarketing experience.
Coumarin Anticoagulants (e.g., Warfarin) Associated with an increase in prothrombin time (Prolonged PT), representing a documented pharmacodynamic effect on blood coagulation.
Probenecid Reduces the total clearance of Cefixime, resulting in an increase in Cefixime plasma concentration by approximately 25%.

Procedural and Population-Specific Constraints

Interactions are not limited to other medicines. Cefixime administration may produce false-positive reactions in certain urine glucose tests (using Benedict's, Fehling's, or Clinitest), urine ketone tests (using nitroprusside), and the Direct Coombs Test.

Furthermore, the official label notes a population-specific consideration: in patients with renal impairment, interaction effects, particularly those involving coagulation changes with anticoagulants, may be exacerbated due to slower drug removal.

Mechanism of Action

Inhibition of Bacterial Cell Wall Synthesis

Xifia, a third-generation cephalosporin, exerts its action by interfering with the synthesis of the bacterial cell wall. The compound functions as an inhibitor by targeting and covalently binding to Penicillin-Binding Proteins (PBPs). These transpeptidases are localized in the bacterial cytoplasmic membrane and are essential for the final cross-linking step of peptidoglycan synthesis.

This binding action modifies the enzymatic activity required for forming the rigid cell wall structure. The subsequent interruption of the cross-linking process leads to osmotic instability, initiating a molecular cascade that results in cell structural failure and degradation.

Beta-Lactamase Resistance

The molecule incorporates a chemical structure that confers a high degree of stability against hydrolysis by many common beta-lactamase enzymes. This structural feature allows the drug to retain its binding affinity for PBPs in the presence of these inactivating enzymes, thereby modulating cellular processes across a wider biological range of susceptible microorganisms.

Dosage and Administration Information

The administration of Xifia (Cefixime) is conducted via the oral route. The medicine is supplied as tablets and capsules (both 400 mg strength), and as an oral suspension for liquid administration. For adults, the standardized regimen is generally 400 mg once daily, or 200 mg administered in two divided doses every 12 hours. The oral dosage forms may be taken without regard to food.

Specific procedural steps are required for proper use. The oral suspension is supplied as a dry powder and must be reconstituted with water prior to initial use; the suspension must be shaken well before measuring each dose. Furthermore, if using the chewable tablet formulation, it must be thoroughly chewed or crushed before being swallowed. The 400 mg tablet is often scored to facilitate division for the twice-daily regimen.

The duration of the regimen is defined by the specific infection, typically ranging from 7 to 14 days. Treatment for infections caused by Streptococcus pyogenes requires a mandatory minimum course of 10 days. Dosage modifications are required for certain populations. Patients with diminished kidney function, such as a creatinine clearance of less than or equal to 20 mL/min, must have their dose reduced to a maximum of 200 mg once daily. For pediatric patients (aged 6 months or older), the dose is based on body weight at 8 mg/kg/day, not to exceed the adult maximum of 400 mg daily.

Recent Clinical Evidence

Research evidence / Overview of studies for Xifia (Cefixime)

The research foundation for Xifia, which contains the active ingredient Cefixime, is built upon multiple clinical studies, primarily Randomized Controlled Trials (RCTs) and comparative trials. This evidence has been used by regulatory bodies for the assessment of the medicine's potential role in specific acute bacterial infections. These studies focus on clinical and microbiological outcomes, providing context on how the medicine was studied for various patient populations and conditions.


Evidence for Use in Common Acute Infections

The evidence base for Cefixime in common acute infections includes trials where other treatments served as comparators. These studies were used in research exploring short-term outcomes reflecting daily functioning and the rates of bacterial clearance.

Research on Throat and Tonsil Infections (Pharyngitis/Tonsillitis)

Short-term RCTs and comparative clinical trials were evaluated in both adult and pediatric patients with conditions involving periods of heightened symptoms in the throat and tonsils. Research primarily examined two main outcomes: the assessment of symptom resolution (clinical cure) and the status of bacteriological eradication for the bacterium Streptococcus pyogenes.

Research on Middle Ear Infections (Acute Otitis Media)

The evidence for Acute Otitis Media (AOM) is largely derived from short-term RCTs and multicenter comparative trials, with a strong focus on pediatric patients. The trials were studied for outcomes related to physical discomfort and assessment of symptom resolution. Evidence is limited in that research derived from the liquid suspension form, often used in children, sometimes restricts the direct comparison of findings across all available formulations.


Evidence in Special Populations and Research Gaps

The research has included specific evaluations for certain demographic groups. Xifia was evaluated in a large body of research for pediatric patients. However, the available clinical studies did not include sufficient numbers of subjects aged 65 and older to fully characterize whether their response patterns differ significantly from younger adults.

Long-term outcomes are not well characterized by the evidence, meaning data on the durability of the response or the frequency of later relapse over several months or years remain insufficient. Furthermore, public health authorities have noted that findings were mixed regarding the susceptibility of bacteria to Cefixime over time, which impacts the certainty of the evidence base.

Key Studies & References WHO Model List of Essential Medicines (Supports classification as essential medicine)

Frequently Asked Questions (FAQ)

Common questions about Xifia (FAQ)

Q: Why is Xifia sometimes mentioned with other similar drugs?

A: Xifia is the trade name for the active ingredient cefixime, which is classified as a third-generation cephalosporin antibiotic. Medicines in this class share structural similarities and mechanisms of action, which is why they are often discussed together in medical literature and official documentation.

Q: How is Xifia different from brand name Y or Z?

A: Xifia is a trade name given to the medication. The underlying active ingredient is cefixime. Other brand names contain the same active ingredient. When discussing differences, it usually refers to the distinction between the trade name and the common generic name of the active compound.

Q: Is Xifia known by any other name?

A: Yes. Xifia is the brand name. The active ingredient is known as cefixime, which is the non-proprietary or generic name.

Q: Is Xifia used for conditions other than the main ones listed?

A: Regulatory documents define the specific bacterial infections for which the medicine is approved. Xifia is formally approved for treating certain conditions, including specific urinary tract infections, throat infections (pharyngitis/tonsillitis), bronchitis, and uncomplicated gonorrhea.

Q: Can I use Xifia if I have kidney problems?

A: Official information states that use requires caution in patients with significantly impaired kidney function. For these patients, dose adjustment is typically necessary. Serious risks, including a brain condition called encephalopathy and acute renal failure, have been reported in patients with markedly reduced kidney function.

Q: Is Xifia safe for older adults?

A: Adverse reactions may occur more frequently in older adults, likely due to the common and expected decrease in kidney function in this age group. Regulatory documentation notes that caution is advised for use in older individuals.

Q: Are there any long-term effects associated with Xifia use?

A: Serious adverse reactions, such as C. difficile-associated diarrhea (CDAD), have been reported during or up to several months after therapy is complete. Official studies have noted that long-term outcomes, particularly regarding the durability of the medication's efficacy, are not well characterized.

Q: Does Xifia lose its effectiveness over time?

A: As with many antibiotics, official warnings note that prolonged or repeated use may result in the overgrowth of non-susceptible organisms (superinfection). Susceptibility tests may be performed by a healthcare provider to determine the medication's effectiveness against the infecting bacteria.

Q: Is it common to feel tired when starting Xifia?

A: Regulatory safety information lists unusual tiredness or weakness as a side effect that may occur while taking this medicine. Any unusual or excessive fatigue should be brought to the attention of a healthcare professional.

Q: Can Xifia cause a metallic taste in the mouth?

A: Official side effect reports list taste alteration as a potential adverse reaction to Xifia. This may be experienced as an unpleasant or metallic taste.

Q: Can Xifia affect my ability to drive or operate machinery?

A: Side effects such as dizziness or drowsiness are listed in the official safety profile. These effects may potentially impair the ability to drive or safely operate complex machinery.

Q: Does Xifia affect blood pressure or heart rate?

A: Regulatory safety notes list irregular heartbeat as a potential symptom associated with underlying kidney problems that may require medical attention. Direct effects on blood pressure are not generally listed as common side effects.

Q: What is the risk of a serious allergic reaction to Xifia?

A: Serious, life-threatening allergic reactions, such as anaphylaxis, are rare but possible. Official documentation notes that the medicine is contraindicated in patients with a history of allergy to cephalosporins or a severe reaction to penicillin.

Q: Do you have to take Xifia at the same exact time every day?

A: Patient information leaflets typically recommend taking the medication at the same time every day. Taking the medication at consistent times helps maintain steady blood levels.

Q: Does Xifia interact with alcohol?

A: Patients are generally advised to consult their healthcare provider about the use of alcohol while taking Xifia. Official prescribing information advises consulting a healthcare provider regarding alcohol use.

Q: What if I take Xifia with certain herbal supplements?

A: Patients are generally advised in official guidelines to inform their healthcare provider of all medicines, vitamins, and herbal supplements they are taking. This practice helps ensure all potential drug-supplement interactions are evaluated.

Q: Does Xifia interact with birth control pills?

A: According to prescribing information, Cefixime may reduce the effectiveness of some oral contraceptives (birth control pills). Discussions with a healthcare provider regarding the need for alternative or additional forms of contraception are advised.

Q: Are there any specific blood tests required while on Xifia?

A: Monitoring of blood work may be performed as needed, particularly for patients with existing kidney or liver problems or those taking anticoagulants. This drug can affect certain lab values like Prothrombin Time (PT) and liver enzymes, and monitoring helps ensure safety.

Q: Is Xifia a controlled substance?

A: Official classification documents indicate that Xifia (Cefixime) is a prescription-only medicine but is not classified as a controlled substance under U.S. federal regulation.

How should Xifia be stored and disposed of?

How to Store and Dispose of Xifia (Cefixime)

The storage and disposal instructions for Xifia (Cefixime) are defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

Dosage Form Required Storage Condition Stability Constraint
Tablets/Capsules/Powder Controlled Room Temperature (20 C to 25 C) Protect from moisture and light
Reconstituted Suspension Controlled Room Temperature OR Refrigerated (2 C to 8 C) Must be discarded after 14 days; Do Not Freeze

The solid forms must be kept in the original, tightly closed container. All medicine must be stored out of the sight and reach of children.

Disposal

Unused or expired Xifia should be disposed of via drug take-back programs. If unavailable, follow government guidelines by mixing the medicine with an undesirable substance before sealing and placing it in household trash. The liquid suspension should not be poured down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xifia found in:

A-Z Index: